Last €88.90 EUR
Change Today -0.90 / -1.00%
Volume 827.0
SANF On Other Exchanges
EN Paris
EN Paris
New York
As of 11:30 AM 10/1/14 All times are local (Market data is delayed by at least 15 minutes).

sanofi (SANF) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/30/14 - €90.05
52 Week Low
02/6/14 - €68.60
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for SANOFI (SANF)

sanofi (SANF) Details

Sanofi researches, develops, manufactures, and markets healthcare products. The company operates in three segments: Pharmaceuticals, Human Vaccines, and Animal Health. Its products include Lantus and Apidra analogs of human insulin; Insuman human insulin solutions and suspensions; Amaryl, a sulfonylurea; BGStar, iBGStar, and MyStar Extra blood glucose meters; enzyme replacement therapies, such as Cerezyme for Gaucher disease, Fabrazyme for Fabry, and Myozyme/Lumizyme for Pompe disease; Aldurazyme, for mucopolysaccharidosis Type I; Aubagio, a immunomodulator for multiple sclerosis; Taxotere, a taxane derivative for cancers; Eloxatine for colorectal cancer; and Jevtana for prostate cancer. The company’s products also comprise thrombosis medicines, such as Plavix anti-platelet agent for atherothrombotic conditions and Lovenox to prevent and treat deep vein thrombosis; and cardiovascular medicines, including Multaq anti-arrhythmic agent and Aprovel/CoAprovel for hypertension treatments. It also offers Renagel/Renvela for patients with chronic kidney disease on dialysis to treat high phosphorus levels; Synvisc and Synvisc-One viscosupplements to treat pain associated with osteoarthritis; and pediatric and influenza, adult and adolescent booster, meningitis and pneumonia, and travel and endemics vaccines. In addition, the company provides pharmaceuticals and vaccines used by veterinarians, farmers, and pet owners; consumer health care products; and generic medicines. Sanofi distributes its products through its sales force, as well as through physicians, pharmacies, hospitals, distributors, veterinaries, chemists, and wholesalers. It has strategic alliances and collaborations with Bristol-Myers Squibb, Regeneron, Warner Chilcott, Regulus Therapeutics Inc., Medtronic, Inc., UCB S.A., and Illumina, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1970 and is headquartered in Paris, France.

112,128 Employees
Last Reported Date: 03/7/14
Founded in 1970

sanofi (SANF) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: €3.0M
Compensation as of Fiscal Year 2013.

sanofi (SANF) Key Developments

Apollo Hospitals and Sanofi Announce Collaboration to Provide an Integrated Care Program in India for People with Diabetes

Apollo Hospitals and Sanofi announced their decision to collaborate on the expansion of Apollo Sugar Clinics, which provide integrated diabetes care programs in India. Through this collaboration, Apollo and Sanofi plan to leverage their respective expertise in diabetes to provide patients with access to comprehensive educational resources, treatment and care programs that can help patients better manage their diabetes. The first wave of this collaboration will focus on the establishment of 50 Apollo Sugar Clinics. In line with concentrated efforts towards controlling the burgeoning diabetes epidemic - both globally and in India, the Apollo Sugar Clinics endeavour is to make diabetes 'disease-free' by offering easy access to an integrated diabetes care solution within a clinical infrastructure, which promotes early detection and treatment of diabetes and associated complications, strengthened by lifestyle management and behaviour change programs. All these together can lead to better compliance with necessary treatments and potentially lead to better patient outcomes.

Sanofi Appoints Jeroen Weites as its New Director General

Sanofi has appointed Jeroen Weites as its new director general. Weites joined the Sanofi team in 2010. He has previously worked for Bristol-Myers Squibb, Organon, Pfizer, Biogen Idec, and Genzyme.

UAE Ministry of Health and Sanofi Partner to Enhance Pharmacists Expertise to Raise Standards of Care

The UAE Ministry of Health (MoH) and Sanofi have signed an agreement to develop the 'Integration Initiative', a series of training courses for clinical, general and drug safety practitioners, as well as pharmacists concerned with scientific research in the UAE. At the signing ceremony of the Integration Initiative between the Ministry of Health and Sanofi, His Excellency Dr. Amin Hussein Al Amiri, Assistant Undersecretary for Public Health and Licensing Sector at the UAE Ministry of Health explained the importance of enhancing the skills, efficiency and performance of pharmacists and other healthcare practitioners to improve the health of people in the UAE. During the period of the initiative, the program aims to train professionals in five key areas; clinical studies and good clinical practices, pharmacoeconomics and health economics, combatting drug counterfeiting, pharmacovigilance and the ideal use of antibiotics.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SANF:IM €88.90 EUR -0.90

SANF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bayer AG €110.49 EUR -0.22
Gilead Sciences Inc $105.76 USD -0.69
GlaxoSmithKline PLC 1,414 GBp +1.00
Merck & Co Inc $58.84 USD -0.44
Pfizer Inc $29.17 USD -0.3953
View Industry Companies

Industry Analysis


Industry Average

Valuation SANF Industry Range
Price/Earnings 26.7x
Price/Sales 3.3x
Price/Book 2.1x
Price/Cash Flow 16.0x
TEV/Sales 2.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SANOFI, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at